Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases

Prospective Survey of Chest X-Rays or Computed Tomography Abnormalities in Patients with Inflammatory Bowel Disease Treated with Infliximab

“…infection, or drugs. The pulmonary lesions noted in this study were different from those reported as being drug-induced in other studies [11,13], and did not change even with continued IFX or mesalazine administration in two cases. Bronchiectatic and granular shadows noted in one case increased during 38-months period.…”

“…For patients with IBD, the incidence of active TB after treatment with an anti-TNF inhibitor was reported to be approximately 1% to 2% [10], whereas the incidence of ILD associated with these inhibitors is unknown. However, there are reported instances of ILD associated with IBD during treatment with anti-TNF inhibitors [11].…”

Extraarticular Manifestations of Rheumatoid Arthritis in Patients under Anti-tumor Necrosis Factor-α Treatment

“…Was an adverse reaction because of other drugs ruled out? Exacerbation and appearance of ILD were reviewed in a large series of 122 patients receiving anti-TNF-α agents 3 . Withdrawal of biologic agents resulted in complete resolution, partial resolution, and no resolution in 40%, 25%, and 35% of patients, respectively.…”

Romatoid artritte akciğer tutulumu

“…Anti-TNF tedavi alan RA-‹AH hastalar›nda bildirilen h›zl› ve fatal olabilen akci¤er hastal›k progresyonu vakalar› bu tedavilerin olumlu sonuçlar›n› tart›flmal› hale getirmifltir. [19] Anti-CD-20 tedavi seçene¤i RA-UIP hastalar›n›n peribronflial lenfoid agregatlar›nda CD20+B hücre-lerinin bulunmas› nedeniyle bu hastalar›n tedavisinde denenmeye bafllanm›flt›r. Yap›lan retrospektif bir çal›flmada rituksimab tedavisi alan ve akci¤er hastal›¤› olan RA hastalar›n 6 y›ll›k izlem sonuçlar›nda güvenli¤i tehdit edici bir durumun saptanmad›¤› bildirilmifltir.…”

“…Mortalite sebebi pulmoner hastal›¤›n progresyonu olarak bildirilmifltir. [19] ‹ngiliz biyolojik tedavi veri taban› sonuçla-r›na göre ise kar›flt›r›c› faktörler düzeltildikten sonra tüm mortalite sebepleri aç›s›ndan RA-‹AH anti-TNF grupda RA-‹AH DMARDs gruba göre mortalite h›z› oran› 0.81 (0.38-1.73) olarak bulunmufltur. [21] Marmara T›p Fakültesi RA klini¤inde anti-TNF tedavinin RA akci¤er patolojileri üzerine etkinli¤ini bir çal›flmada inceledik.…”